Concentrated methotrexate solutions
AssigneeMedac Gesellschaft Fuer Klinische Spezialpraepararate Mbh
InventorHeiner WILL
Life of this patent
Estimating the term…
Abstract
Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.
Claims30
A method for treating an inflammatory autoimmune disease in a patient in need thereof, the method comprising subcutaneously administering to said patient a pharmaceutical solution comprising methotrexate in a pharmaceutically acceptable solvent at a concentration of 50 to 150 mg/ml.
Dependencies are inferred from the claim text.